Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Mireca Medicine

Mireca Medicine is a pre-clinical stage ophthalmology start-up company seated in Tübingen (Germany) aiming to bring its targeted, small molecule drug candidate to patients suffering from previously incurable hereditary retinal diseases. Mireca Medicine is connected to an international research network.

Mireca Medicine's website

Mireca Medicine

Developing small molecules to treat a broad band of photoreceptor mutations.

Mireca Medicines was founded to continue the R&D work originating from FP7 project DRUGSFORD. All DRUGSFORD consortium members are founding shareholders of Mireca.

From Lund University: Per Ekström, Ophthalmology at the Department of Clinical Sciences.

Portfolio company since 2017.

Portfolio Manager LU Holding:

christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78

8 Sep 2020